MedCity News July 28, 2021
Frank Vinluan

Softbank led the Series C round of funding for Deep Genomics, a startup that applies its artificial intelligence technology to all aspects of discovering and developing new drugs. The Deep Genomics platform has yielded 10 programs; CEO Brendan Frey aims to advance four of them to the clinic in two years, all while tripling the company’s pipeline.

Drug discovery and development is advancing by leaps and bounds as genetic medicines progress under a growing number of biotech companies. In the view of Brendan Frey, founder and CEO of startup Deep Genomics, while the drugs of the 20th century revolved around small molecule chemistry, drugs of the 21st century will be based on information: the sequence of letters in genetic code...

Today's Sponsors

Transcarent
SalesSparx
Canton & Company

Today's Sponsors

Oscar
Curation Health

Today's Sponsor

TripleTree

 
Topics: AI (Artificial Intelligence), Biotechnology, Investments, Pharma / Biotech, Technology, Trends
AION Labs, Biotech Innovation Lab Launched by Top Pharma, Tech and Investment Leaders
Bionano frames $90M BioDiscovery buy as way to expand genomics analysis
CRISPR touts new results as fresh questions surround 'off-the-shelf' CAR-T
Takeda takes aim at a biotech's gene therapy work
Genomics study unlocks secrets of the past to help shape future of healthcare for millions